"There is still a great deal of variation across the country on which treatments patients are able to access and so I am hopeful the Scorecard will help highlight discrepancies which can then be addressed.
"The Scorecard is a definite step forward and I think it is particularly important that there is a focus on the uptake of new medicines, as UK patients still don’t receive the latest treatments as quickly as their European counterparts. This is not only bad for the health of the nation, but also means we lose the opportunity to drive efficiency savings through the use of medicines, which can often reduce the need for expensive hospital care.
"We also welcome other moves to support the use of NICE recommended treatments, such as automatically including medicines on to local medicine availability lists and the creation of a group to help local NHS organisations implement NICE guidelines."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.